GlassScriptPhysician profile
Amber Lynn Guy
NPI 1003524919
$2,158.10
in general payments reported to CMS, 2019-2025
31 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,226 · 2024: $438 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,158.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.75 | 2023-2025 | |
| Lilly USA, LLC | $278.27 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $212.04 | 2023-2024 | |
| Glaxosmithkline, LLC. | $203.13 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $127.51 | 2023-2025 | Airsupra, Farxiga |
| Pfizer INC. | $115.34 | 2023-2024 | |
| Novo Nordisk INC | $112.56 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $103.41 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $82.26 | 2023 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $71.50 | 2024-2025 | Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $64.58 | 2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $54.01 | 2025 | Fanapt, Hetlioz |
| Merck Sharp & Dohme LLC | $50.02 | 2023-2025 | Verquvo, Belsomra, Steglatro |
| Indivior INC. | $36.04 | 2025 | Sublocade |
| Halozyme INC | $30.68 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.92 | 2023-2024 | Synjardy, Jardiance, Tradjenta |
| Almatica Pharma LLC | $26.61 | 2023 | Loreev Xr |
| Gilead Sciences, INC. | $24.27 | 2025 | |
| Esperion Therapeutics, INC. | $23.30 | 2023 | Nexletol |
| Janssen Pharmaceuticals, INC | $23.04 | 2023 | Xarelto |
| Xeris Pharmaceuticals, INC. | $22.45 | 2023 | Gvoke Hypopen |
| Kyowa Kirin, INC. | $21.93 | 2023 | Crysvita |
| Corcept Therapeutics | $20.87 | 2025 | Korlym |
| Antares Pharma, INC. | $20.15 | 2023 | Xyosted, Tlando, Nocdurna |
| Sumitomo Pharma America, INC. | $20.06 | 2023 | Gemtesa |
| Mylan Specialty L.P. | $19.21 | 2023 | Yupelri |
| Hologic Sales and Service, LLC | $17.83 | 2023 | Aptima |
| Amgen INC. | $17.05 | 2025 | Repatha, Otezla |
| Lundbeck LLC | $16.92 | 2023 | Vyepti |
| Exact Sciences Corporation | $15.16 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.23 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Guy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.